ResMed Inc. (RMD)
NYSE: RMD · Real-Time Price · USD
282.35
-0.93 (-0.33%)
At close: Oct 8, 2025, 4:00 PM EDT
283.69
+1.34 (0.47%)
After-hours: Oct 8, 2025, 7:34 PM EDT
ResMed Stock Forecast
Stock Price Forecast
The 9 analysts that cover ResMed stock have a consensus rating of "Buy" and an average price target of $288.89, which forecasts a 2.32% increase in the stock price over the next year. The lowest target is $269 and the highest is $330.
Price Target: $288.89 (+2.32%)
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for ResMed stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | May '25 | Jun '25 | Jul '25 | Aug '25 | Sep '25 | Oct '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 3 | 3 | 3 | 3 | 3 | 2 |
| Buy | 4 | 4 | 6 | 6 | 6 | 6 |
| Hold | 5 | 5 | 3 | 3 | 3 | 3 |
| Sell | 1 | 1 | 1 | 1 | 1 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 13 | 13 | 13 | 13 | 13 | 11 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Citigroup | Citigroup | Strong Buy Initiates $330 | Strong Buy | Initiates | $330 | +16.88% | Sep 18, 2025 |
| Mizuho | Mizuho | Buy Maintains $270 → $290 | Buy | Maintains | $270 → $290 | +2.71% | Aug 1, 2025 |
| Stifel | Stifel | Hold Maintains $240 → $270 | Hold | Maintains | $240 → $270 | -4.37% | Aug 1, 2025 |
| RBC Capital | RBC Capital | Buy Maintains $294 → $300 | Buy | Maintains | $294 → $300 | +6.25% | Aug 1, 2025 |
| UBS | UBS | Strong Buy Maintains $285 → $325 | Strong Buy | Maintains | $285 → $325 | +15.11% | Aug 1, 2025 |
Financial Forecast
Revenue This Year
5.65B
from 5.15B
Increased by 9.69%
Revenue Next Year
6.06B
from 5.65B
Increased by 7.26%
EPS This Year
10.95
from 9.51
Increased by 15.13%
EPS Next Year
12.01
from 10.95
Increased by 9.69%
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | 6.0B | 6.5B | |||
| Avg | 5.6B | 6.1B | |||
| Low | 5.4B | 5.7B |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | 16.1% | 14.3% | |||
| Avg | 9.7% | 7.3% | |||
| Low | 5.1% | 1.8% |
EPS Forecast
| EPS | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | 12.60 | 13.10 | |||
| Avg | 10.95 | 12.01 | |||
| Low | 10.11 | 11.27 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | 32.5% | 19.7% | |||
| Avg | 15.1% | 9.7% | |||
| Low | 6.3% | 2.9% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.